ONCT News and Press, Oncternal Therapeutics Inc. From 08/08/19

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen of cirmtuzumab + ibrutinib supports opening Phase 2 Two product candidates moving forward in clinical trials Conference c...

SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc., (Nasdaq: ONCT) a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that it has opened for enrollment its randomi...

SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical need, today announced that it will report second quarter 2019 finan...